ZAZZI MAURIZIO | Elenco docenti

Rossetti, B., Ferrara, M., Taramasso, L., Bai, F., Lombardi, F., Ciccarelli, N., et al. (2022). THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN VIROLOGICALLY SUPPRESSED PEOPLE LIVING WITH HIV ON NEUROPSYCHIATRIC SYMPTOMS: PRELIMINARY FINDINGS FROM A RANDOMIZED STUDY. In Atti al 14th Congresso ICAR 2022 (Italian Conference on AIDS and Antiviral Research). - dettaglio
Kuznetsova, A., Lebedev, A., Gromov, K., Kazennova, E., Zazzi, M., Incardona, F., et al. (2022). Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first-line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus-infected patients. CLINICAL CASE REPORTS, 10(2), e05373 [10.1002/ccr3.5373]. - dettaglio
Dragoni, F., Rossetti, B., Lombardi, F., Raffaelli, C.S., Bartolini, N., Giammarino, F., et al. (2022). Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, Publish Ahead of Print [10.1097/QAI.0000000000003073]. - dettaglio
Vicenti, I., Basso, M., Dragoni, F., Gatti, F., Scaggiante, R., Fiaschi, L., et al. (2022). Comparable Post-Vaccination Decay of Neutralizing Antibody Response to Wild-Type and Delta SARS-CoV-2 Variant in Healthcare Workers Recovered from Mild or Asymptomatic Infection. VACCINES, 10(4), 580 [10.3390/vaccines10040580]. - dettaglio
Gagliardini, R., Baccini, M., Modica, S., Montagnani, F., Zanelli, G., Borghetti, A., et al. (2022). Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 28, 274-281 [10.1016/j.jgar.2022.01.018]. - dettaglio

Tutte le pubblicazioni